Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS • Currently up 8.30 (+2.76%) in today's trading session

1 member of Congress has disclosed 2 trades in Alnylam Pharmaceuticals, Inc. (ALNY) via STOCK Act filings. The most recent disclosure was a sale by Josh Gottheimer on 11 December 2023. Aggregate disclosed activity totals roughly $8K in purchases and $8K in sales (midpoint estimates from bracketed disclosure amounts).

Alnylam Pharmaceuticals, Inc. is currently trading at $309.49, positioned at 25% of its 52-week range ($245.96 – $495.55).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Free asset at sign up • Eligible regions only
Copy PortfolioClaim Free Asset
Live portfolio tracking
Automatic rebalancing

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Not available in the US.

Past Performance is not an indication of future results.

*Free asset promotion available at sign up in eligible regions only. Terms and conditions apply.

Current Price
$309.49
24h Change
+8.30 (+2.76%)
52 Week Range
$245.96—$495.55
View on NASDAQ

Alnylam Pharmaceuticals, Inc. Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for ALNY

Select to highlight on chart
2 transactions
Compliance: 100%
Josh Gottheimer11 Dec 20237 Jan 2024SaleStock$1,001 - $15,000N/A
Josh Gottheimer28 Sept 202216 Oct 2022PurchaseStock$1,001 - $15,000N/A

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$41.39B

Volume

1.35M

Beta

0.38

P/E Ratio

133.69

Fundamentals

EPS

$2.32

Div. Yield

—

Open

$307.48

Day Range

$287.00 — $317.55

Company Information

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ · USD
Country
US
CEO
Yvonne L. Greenstreet
IPO Date
2004-06-01
Website
www.alnylam.com

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on gene...

Earnings

Next Report

Q1 2026

30 Apr

EPS Est.

$1.43

Rev. Est.

$1.1B

Days Until

0

Recent Quarters

Q4 202512 Feb
EPS$0.82
Miss 29.3%
Q3 202530 Oct
EPS$2.90
Beat 416.9%
Q2 202531 Jul
EPS$0.32
Beat 158.8%
Q1 20251 May
EPS$-0.01
Beat 98.9%
Q4 202413 Feb
EPS$0.06
Beat 109.7%
Q3 202431 Oct
EPS$-0.50
Beat 45.5%
Q2 20241 Aug
EPS$0.56
Beat 152.3%
Q1 20242 May
EPS$-0.16
Beat 85.7%
Q4 202315 Feb
EPS$-1.10
Beat 8.3%
Q3 20232 Nov
EPS$1.15
Beat 185.8%
Q2 20233 Aug
EPS$-2.21
Miss 28.5%
Q1 20234 May
EPS$-1.40
Beat 28.9%
Q4 202223 Feb
EPS$-1.68
Beat 21.1%
Q3 202227 Oct
EPS$-3.32
Miss 78.5%
Q2 202228 Jul
EPS$-2.29
Miss 41.4%
Q1 202228 Apr
EPS$-2.00
Miss 3.6%
Q4 202110 Feb
EPS$-2.16
Miss 46.9%
Q3 202128 Oct
EPS$-1.72
Miss 13.9%
Q2 20213 Aug
EPS$-1.61
Miss 2.5%
Q1 202129 Apr
EPS$-1.71
Beat 2.3%
Q4 202011 Feb
EPS$-2.09
Miss 8.3%
Q3 20205 Nov
EPS$-2.18
Miss 24.6%
Q2 20206 Aug
EPS$-1.56
Beat 12.8%
Q1 20206 May
EPS$-1.62
Beat 14.3%
Q4 20196 Feb
EPS$-2.47
Miss 9.8%
Q3 201931 Oct
EPS$-1.92
Beat 11.5%
Q2 20196 Aug
EPS$-1.83
Miss 1.1%
Q1 20191 May
EPS$-1.42
Beat 22.8%
Q4 20187 Feb
EPS$-1.82
Beat 7.6%
Q3 20187 Nov
EPS$-1.56
Beat 9.8%
Q2 20182 Aug
EPS$-1.61
Miss 4.5%
Q1 20183 May
EPS$-1.22
Miss 3.4%
Q4 20178 Feb
EPS$-1.48
Miss 7.3%
Q3 20177 Nov
EPS$-1.06
Beat 13.8%
Q2 20179 Aug
EPS$-1.07
Beat 9.3%
Q1 20175 May
EPS$-1.25
Miss 2.5%
Q4 20168 Feb
EPS$-1.32
Beat 2.2%
Q3 20162 Nov
EPS$-1.21
Miss 1.7%
Q2 20164 Aug
EPS$-1.05
Beat 16.7%
Q1 20162 May
EPS$-1.21
Miss 12.0%
Q4 201511 Feb
EPS$-1.07
Miss 5.9%
Q3 20159 Nov
EPS$-0.91
Beat 3.2%
Q2 20156 Aug
EPS$-0.85
Miss 14.9%
Q1 20157 May
EPS$-0.62
Beat 4.6%
Q4 201412 Feb
EPS$-0.11
Beat 80.7%
Q3 20145 Nov
EPS$-0.50
Beat 23.1%
Q2 20147 Aug
EPS$-0.63
Miss 16.7%
Q1 20148 May
EPS$-0.39
Beat 67.0%
Q4 201313 Feb
EPS$-0.42
Beat 12.5%
Q3 20136 Nov
EPS$-0.34
Beat 10.5%
Q2 20138 Aug
EPS$-0.24
Beat 29.4%
Q1 20136 May
EPS$-0.10
Beat 67.7%
Q4 20127 Feb
EPS$-0.54
Beat 68.2%
Q3 20125 Nov
EPS$-0.31
Beat 0.0%
Q2 20126 Aug
EPS$-0.25
Miss 31.6%
Q1 20123 May
EPS$-0.25
Beat 30.6%
Q4 20119 Feb
EPS$-0.33
Miss 3.1%
Q3 20111 Nov
EPS$-0.31
Beat 11.4%
Q2 20111 Aug
EPS$-0.33
Beat 8.3%
Q1 20112 May
EPS$-0.38
Miss 26.7%
Q4 201017 Feb
EPS$-0.16
Beat 54.3%
Q3 20103 Nov
EPS$-0.23
Beat 42.5%
Q2 20104 Aug
EPS$-0.35
Miss 16.7%
Q1 20105 May
EPS$-0.29
Beat 3.3%
Q4 200925 Feb
EPS$-0.19
Beat 36.7%
Q3 20094 Nov
EPS$-0.22
Beat 8.3%
Q2 20096 Aug
EPS$-0.55
Miss 12.2%
Q1 20097 May
EPS$-0.19
Beat 17.4%
Q4 200824 Feb
EPS$-0.23
Miss 53.3%
Q3 20085 Nov
EPS$-0.07
Beat 58.8%
Q2 20086 Aug
EPS$-0.31
Miss 106.7%
Q1 20088 May
EPS$-0.03
Beat 78.6%
Q4 20077 Feb
EPS$0.04
Beat 118.2%
Q3 20071 Nov
EPS$-1.35
Miss 35.0%
Q2 20079 Aug
EPS$-0.34
Miss 41.7%
Q1 20079 May
EPS$-0.58
Miss 107.1%
Q4 20067 Feb
EPS$-0.26
Beat 13.3%
Q3 20062 Nov
EPS$-0.23
Beat 28.1%
Q2 200626 Jul
EPS$-0.31
Miss 10.7%
Q1 20069 May
EPS$-0.30
Beat 23.1%
Q4 200515 Feb
EPS$-0.56
Miss 14.3%
Q3 20059 Nov
EPS$-0.51
Miss 50.0%
Q2 20053 Aug
EPS$-0.54
Miss 50.0%
Q1 200511 May
EPS$-0.32
Beat 0.0%
Q4 200415 Feb
EPS$-0.29
Miss 38.1%
Q3 200410 Nov
EPS$-0.33
Beat 8.3%
Q2 200412 Aug
EPS$-0.99
Q2 20044 Aug
EPS$-1.10
Miss 89.7%
Q3 200331 Dec
EPS$-3.78
Q2 200330 Sept
EPS$-7.41
Q1 200330 Jun
EPS$-6.02
Q4 200231 Mar
EPS$-4.62

1 politician traded within 30 days

No dividend data available for this stock.

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations
No similar stocks found
No congressional trading patterns available for recommendations

Frequently Asked Questions about ALNY

Which members of Congress have traded ALNY?
1 member of Congress has disclosed 2 trade in Alnylam Pharmaceuticals, Inc. (ALNY) under the STOCK Act: Josh Gottheimer.
When was ALNY most recently disclosed by Congress?
The most recent ALNY disclosure was a sale by Josh Gottheimer on 11 December 2023.
What is the total disclosed congressional trading volume for ALNY?
Members of Congress have disclosed approximately $8K in ALNY purchases and $8K in sales. These figures are midpoint estimates derived from the bracketed amount ranges used in STOCK Act filings.
How can I track new congressional trades in ALNY?
This ALNY page updates as soon as new STOCK Act disclosures are filed for Alnylam Pharmaceuticals, Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi TrackerJoin our Discord
PoliticiansPortfoliosPricingLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
This website is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office, or her representatives. Any use of her name is solely for the purpose of discussing publicly available information.The information provided on this website is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.